AlphaQuest LLC Lowers Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

AlphaQuest LLC lessened its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 94.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 516 shares of the specialty pharmaceutical company's stock after selling 9,377 shares during the period. AlphaQuest LLC's holdings in ANI Pharmaceuticals were worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the company. US Bancorp DE lifted its holdings in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after purchasing an additional 531 shares during the last quarter. KBC Group NV increased its position in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after buying an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ANI Pharmaceuticals by 24.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock valued at $177,000 after buying an additional 579 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at approximately $222,000. Finally, Hohimer Wealth Management LLC purchased a new position in shares of ANI Pharmaceuticals during the third quarter worth approximately $264,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

Remove Ads

ANI Pharmaceuticals Price Performance

ANIP traded up $0.35 during trading on Tuesday, reaching $66.33. 536,707 shares of the stock were exchanged, compared to its average volume of 241,863. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -120.60 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81. The business's 50 day moving average price is $59.63 and its two-hundred day moving average price is $58.14.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ANIP shares. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. Finally, StockNews.com upgraded ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $79.75.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares of the company's stock, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock valued at $191,776. Insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.